Publicacións en colaboración con investigadores/as de Hospital Ramón y Cajal (18)

2024

  1. First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN

    Breast Cancer Research and Treatment, Vol. 206, Núm. 2, pp. 317-328

  2. Meta-analysis of genome-wide association studies for cancer therapy-related cardiovascular dysfunction and functional mapping highlight an intergenic region close to TP63

    Scientific Reports, Vol. 14, Núm. 1

2022

  1. Increased quality of life in patients with breakthrough cancer pain after individualized therapy: the CAVIDIOM study

    Future oncology (London, England), Vol. 18, Núm. 35, pp. 3913-3927

  2. SEOM-GETTHI clinical guideline for the practical management of molecular platforms (2021)

    Clinical and Translational Oncology, Vol. 24, Núm. 4, pp. 693-702

2021

  1. Early clinical experience with trifluridine/tipiracil for refractory metastatic colorectal cancer: The ros study

    Cancers, Vol. 13, Núm. 18

  2. Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure–response analysis

    Cancer Chemotherapy and Pharmacology, Vol. 87, Núm. 1, pp. 113-124

  3. Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer

    npj Precision Oncology, Vol. 5, Núm. 1

  4. Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications

    JCO oncology practice, Vol. 17, Núm. 8, pp. e1162-e1169

2019

  1. Active study: undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain (BTcP)

    Clinical and Translational Oncology, Vol. 21, Núm. 3, pp. 380-390

  2. Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer (Scientific Reports, (2019), 9, 1, (2589), 10.1038/s41598-019-39291-2)

    Scientific Reports

  3. Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. Assessment and treatment of breakthrough cancer pain in Spain: A self-audit study

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii611-viii612

  2. Clinical practice evaluation of opioids induced constipation management in oncologic patients: The EIO-50 project

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii612

  3. Oncologist’s knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study

    Clinical and Translational Oncology, Vol. 20, Núm. 5, pp. 613-618

  4. The quality oncology practice initiative program: Experience in Spain

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii570-viii571

2016

  1. Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis

    The Lancet Oncology, Vol. 17, Núm. 10, pp. 1386-1395

2015

  1. Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer

    International Journal of Cancer, Vol. 136, Núm. 8, pp. 1863-1873

2014

  1. Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists

    Clinical and Translational Oncology, Vol. 16, Núm. 10, pp. 914-920